Brought to you by 
Unity Biotechnology raises $116mm through Series B round; $35mm extension added
18 Aug 2017
Executive Summary
Unity Biotechnology Inc. raised $116mm through its Series B round from new investors Arch Venture Partners, Baillie Gifford, Fidelity Management & Research Co., Partner Fund Management, and Venrock, along with Bezos Expeditions and returning backers Wuxi PharmaTech and Mayo Clinic Ventures. Unity is developing therapies to selectively eliminate senescent cells from the body to treat diseases of aging. Series B proceeds will help expand R&D activities and advance the first preclinical candidates (for inflammatory joint diseases and ophthalmic conditions) into clinical trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Unity Biotechnology raises $116mm through Series B round; $35mm extension added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice